HALO — Halozyme Therapeutics Share Price
0.000.00%
Last trade - 00:00- $7.47bn
- $8.38bn
- $1.02bn
- 100
- 39
- 99
- 94
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.7 | ||
| PEG Ratio (f) | 0.36 | ||
| EPS Growth (f) | 41.83% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 20.54 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 15.95 | ||
| Price to Sales | 7.36 | ||
| EV to EBITDA | 13.25 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 28.66% | ||
| Return on Equity | 198.42% | ||
| Operating Margin | 54.32% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 267.59 | 443.31 | 660.12 | 829.25 | 1,015.32 | 1,195.46 | 1,484.45 | 38.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +210.81 | -44.3 | +33.79 | +62.36 | +50.82 | +29.04 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Directors
- Connie Matsui CHM (67)
- Helen Torley PRE (58)
- Nicole Labrosse CFO
- Michael LaBarre SVP (49)
- Mark Snyder SVP
- Jean-Pierre Bizzari IND (66)
- Bernadette Connaughton IND (63)
- James Daly IND (59)
- Jeffrey Henderson IND (56)
- Matthew Posard IND (48)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 23rd, 2007
- Public Since
- January 30th, 2003
- No. of Shareholders
- 136,528
- No. of Employees
- 350
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 123,533,310
- Address
- 12390 EL CAMINO REAL, SAN DIEGO, 92130
- Web
- https://www.halozyme.com/
- Phone
- +1 8587948889
- Contact
- Tram Bui
- Auditors
- Ernst & Young LLP
Upcoming Events for HALO
Q1 2025 Halozyme Therapeutics Inc Earnings Release
Q2 2025 Halozyme Therapeutics Inc Earnings Release
Similar to HALO
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Halozyme Therapeutics share price?
As of Today at 21:00 UTC, shares in Halozyme Therapeutics are trading at $60.49. This share price information is delayed by 15 minutes.
How has the Halozyme Therapeutics share price performed this year?
Shares in Halozyme Therapeutics last closed at $60.49 and the price had moved by +57.28% over the past 365 days. In terms of relative price strength the Halozyme Therapeutics share price has outperformed the S&P500 Index by +45.18% over the past year.
What are the analyst and broker recommendations for Halozyme Therapeutics?
The overall consensus recommendation for Halozyme Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Halozyme Therapeutics dividend yield?
Halozyme Therapeutics does not currently pay a dividend.
Does Halozyme Therapeutics pay a dividend?
Halozyme Therapeutics does not currently pay a dividend.
When does Halozyme Therapeutics next pay dividends?
Halozyme Therapeutics does not currently pay a dividend.
How do I buy Halozyme Therapeutics shares?
To buy shares in Halozyme Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Halozyme Therapeutics?
As of the previous close price of $60.49, shares in Halozyme Therapeutics had a market capitalisation of $7.47bn.
Where are Halozyme Therapeutics shares listed?
Here are the trading details for Halozyme Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: HALO
What kind of share is Halozyme Therapeutics?
Based on an overall assessment of its quality, value and momentum Halozyme Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Halozyme Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Halozyme Therapeutics is $69.57. That is 15.01% above the last closing price of $60.49.
Analysts covering Halozyme Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $5.18 for the next financial year.
Find out moreWhat is the trend in the Halozyme Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Halozyme Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +29.45%.
As of the last closing price of $60.49, shares in Halozyme Therapeutics were trading +8.02% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Halozyme Therapeutics PE Ratio?
The Halozyme Therapeutics PE ratio based on its reported earnings over the past 12 months is 10.7. The shares last closed at $60.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Halozyme Therapeutics?
Halozyme Therapeutics' management team is headed by:
- Connie Matsui - CHM
- Helen Torley - PRE
- Nicole Labrosse - CFO
- Michael LaBarre - SVP
- Mark Snyder - SVP
- Jean-Pierre Bizzari - IND
- Bernadette Connaughton - IND
- James Daly - IND
- Jeffrey Henderson - IND
- Matthew Posard - IND